Presentation is loading. Please wait.

Presentation is loading. Please wait.

Presented By Johanna Bendell at 2016 ASCO Annual Meeting

Published bySuryadi Sudirman Modified over 6 years ago

Similar presentations

Presentation on theme: "Presented By Johanna Bendell at 2016 ASCO Annual Meeting"— Presentation transcript:

1 Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Clinical activity and safety of cobimetinib and atezolizumab in colorectal cancer Presented By Johanna Bendell at 2016 ASCO Annual Meeting

2 Colorectal Cancer: Unmet Need
Presented By Johanna Bendell at 2016 ASCO Annual Meeting

3 Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Slide 3 Presented By Johanna Bendell at 2016 ASCO Annual Meeting

4 Atezolizumab: An Anti-PDL1 Antibody
Presented By Johanna Bendell at 2016 ASCO Annual Meeting

5 PD-L1 and MEK Inhibition: A Rational Combination
Presented By Johanna Bendell at 2016 ASCO Annual Meeting

6 Phase Ib Dose Escalation and Cohort Expansion Study (NCT01988896)
Presented By Johanna Bendell at 2016 ASCO Annual Meeting

7 Phase Ib Dose Escalation and Cohort Expansion Study (NCT01988896)
Presented By Johanna Bendell at 2016 ASCO Annual Meeting

8 Baseline Characteristics
Presented By Johanna Bendell at 2016 ASCO Annual Meeting

9 Baseline Characteristics (cont.)
Presented By Johanna Bendell at 2016 ASCO Annual Meeting

10 Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Safety Summary Presented By Johanna Bendell at 2016 ASCO Annual Meeting

11 Safety: Treatment-related AEs
Presented By Johanna Bendell at 2016 ASCO Annual Meeting

12 Efficacy: Confirmed Objective Response
Presented By Johanna Bendell at 2016 ASCO Annual Meeting

13 Efficacy: Change in Tumor Burden
Presented By Johanna Bendell at 2016 ASCO Annual Meeting

14 Efficacy: Change in Tumor Burden Over Time
Presented By Johanna Bendell at 2016 ASCO Annual Meeting

15 Efficacy: Duration of Treatment and Response
Presented By Johanna Bendell at 2016 ASCO Annual Meeting

16 Efficacy: Progression-Free Survival And Overall Survival
Presented By Johanna Bendell at 2016 ASCO Annual Meeting

17 Biomarkers: CD8 T-cell Accumulation and MHC I Expression
Presented By Johanna Bendell at 2016 ASCO Annual Meeting

18 Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Summary Presented By Johanna Bendell at 2016 ASCO Annual Meeting

19 Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Summary Presented By Johanna Bendell at 2016 ASCO Annual Meeting

20 Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Acknowledgments Presented By Johanna Bendell at 2016 ASCO Annual Meeting

Download ppt "Presented By Johanna Bendell at 2016 ASCO Annual Meeting"

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Moskowitz CH et al. Proc ASH 2014;Abstract 290.

Moskowitz CH et al. Proc ASH 2014;Abstract 290.
Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.

Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.
Highlights of the Day II: SARCOMA “The not so Old and the New” Presented By Dennis Priebat at 2014 ASCO Annual Meeting.

Highlights of the Day II: SARCOMA “The not so Old and the New” Presented By Dennis Priebat at 2014 ASCO Annual Meeting.
Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.
A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.
Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.
Title, in bold style Subtitle, in regular Max 3 lines of text totally NB! The graphic outside the slide will not show in “Slide Show” or on print WntResearch.

Title, in bold style Subtitle, in regular Max 3 lines of text totally NB! The graphic outside the slide will not show in “Slide Show” or on print WntResearch.
Lesokhin AM et al. Proc ASH 2014;Abstract 291.

Lesokhin AM et al. Proc ASH 2014;Abstract 291.
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
Phase I Trial of Sorafenib in High-Risk Hepatocellular Carcinoma (HCC) Patients After Liver Transplantation (LT) AB Siegel, R Hidalgo, D Tsushima, J Zaretsky,

Phase I Trial of Sorafenib in High-Risk Hepatocellular Carcinoma (HCC) Patients After Liver Transplantation (LT) AB Siegel, R Hidalgo, D Tsushima, J Zaretsky,
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.
Genes and Function: The Rewriting of our Textbooks of Pathology Presented By David Hafler at 2014 ASCO Annual Meeting.

Genes and Function: The Rewriting of our Textbooks of Pathology Presented By David Hafler at 2014 ASCO Annual Meeting.
Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.
Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.
Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.

Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.
May 29 - June 2, 2015 TIGER-X: Rociletinib Activity in EGFR T790M Mutant NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* *CCO.

May 29 - June 2, 2015 TIGER-X: Rociletinib Activity in EGFR T790M Mutant NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* *CCO.

Similar presentations

Ads by Google